Orchestra BioMed Holdings, Inc. officer and director Darren Sherman filed a Form 144 notice on November 2, 2026, proposing to sell 15,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ.

Key Highlights

  • Proposed sale: 15,000 shares of Orchestra BioMed Holdings common stock with an aggregate market value of $88,800.00.
  • Seller: Darren Sherman, disclosed as both an officer and a director of the issuer.
  • Source of shares: Shares were acquired through restricted stock vesting from the issuer: 7,477 shares on November 25, 2024, and 7,523 shares on May 18, 2025, both classified as compensation.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of December 18, 2025.
  • Prior three-month sales: Sherman sold 15,000 shares on August 3, 2026 (gross proceeds $61,291.68), 15,000 shares on September 1, 2026 (gross proceeds $74,059.38), and 15,000 shares on October 1, 2026 (gross proceeds $95,447.62).
  • Shares outstanding: According to the filing, 60,105,049 shares of common stock were outstanding at the time of the notice.

Sherman's Proposed November 2026 Sale Under Rule 144

According to the Form 144 filed with the SEC on November 2, 2026, Darren Sherman, an officer and director of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), intends to sell 15,000 shares of the company's common stock. The filing lists the broker as Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, with an approximate sale date of November 2, 2026. The aggregate market value of the proposed sale is reported as $88,800.00.

The shares proposed for sale were acquired through restricted stock vesting directly from the issuer. Specifically, the filing identifies 7,477 shares vesting on November 25, 2024, and 7,523 shares vesting on May 18, 2025, both categorized as compensation. The filing also notes that Sherman's proposed sale is conducted pursuant to a Rule 10b5-1 plan adopted on December 18, 2025. Under that plan, Sherman has executed three prior sales in the preceding three months: 15,000 shares on August 3, 2026 for gross proceeds of $61,291.68; 15,000 shares on September 1, 2026 for gross proceeds of $74,059.38; and 15,000 shares on October 1, 2026 for gross proceeds of $95,447.62.

The Form 144 was signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Darren Sherman. The filing states that the total shares of common stock outstanding at the time of the notice were 60,105,049. Orchestra BioMed Holdings is headquartered at 150 Union Square Drive, New Hope, Pennsylvania 18938.

What Was Disclosed

A Form 144 notice was filed on November 2, 2026, disclosing Darren Sherman's proposed sale of 15,000 Orchestra BioMed Holdings common shares valued at $88,800.00, with shares sourced from restricted stock vesting events in 2024 and 2025, conducted under a Rule 10b5-1 plan adopted December 18, 2025.